Research on Bruton's tyrosine kinase inhibitor for the treatment of primary immune-privileged site large B-cell lymphoma
10.12354/j.issn.1000-8179.2023.20231013
- VernacularTitle:BTK抑制剂治疗原发免疫豁免部位大B细胞淋巴瘤的研究进展
- Author:
Binbin DING
1
;
Zijian LI
Author Information
1. 兰州大学第一临床医学院,兰州大学第一医院血液科(兰州市 730000)
- Keywords:
Bruton's tyrosine kinase(BTK)inhibitor;
primary immune-privileged site large B-cell lymphoma(IP-DLBCLs);
therapeutic ef-fect;
security
- From:
Chinese Journal of Clinical Oncology
2023;50(22):1174-1179
- CountryChina
- Language:Chinese
-
Abstract:
Primary immune-privileged site large B-cell lymphoma(IP-DLBCLs)is a general term introduced in the 5th edition of the World Health Organization(WHO)Classification of Lymphoid Tumors and refers to a group of aggressive B-cell lymphomas that originate in sites behind the immune barrier in immunocompetent patients.Anatomical-derived immune sanctuaries(such as the blood-brain,blood-retinal,and blood-testicular barriers)and immunomodulatory systems that share the same immunophenotype and molecular characteristics cur-rently include the central nervous,vitreoretinal,and testes systems and large B-cell lymphomas.The primary immune-privileged site large B-cell lymphoma prognosis is relatively poor,with no standard treatment plan.Toll-like receptor-mediated nuclear factor kappa B(NF-κB)(via MYD88 mutation)and B-cell receptor(BCR)(via CD79B mutation)pathway activation was the core pathogenesis mechanism in all three sys-tems(central nervous,vitreoretinal,and testes),presenting a potential common treatment target.Bruton's tyrosine kinase(BTK)is a central molecule in the above signaling pathway,thus BTK inhibitors present a reasonable therapeutic drug choice for such diseases.This article re-views the mechanism of action,clinical studies,adverse reactions,and drug resistance of BTK inhibitors in primary immune-priviledged site large B-cell lymphoma treatment.
